Quantcast
Get breaking news alerts via email

Click here to manage your alerts
Utah’s Intermountain Healthcare, Myriad Genetics sign research pact

Accord » Effort will help assess value of diagnostic tests.

First Published May 22 2012 09:23 am • Last Updated May 22 2012 06:53 pm

Utah’s Myriad Genetics and Intermountain Healthcare have signed a research agreement to evaluate the effectiveness of Myriad’s diagnostic tests in improving the care and treatment of patients.

The first project under the new collaboration, which is expected to last about a year, will be to "further test the utility" of Myriad’s prostate cancer test.

Join the Discussion
Post a Comment

Myriad’s test, marketed under the name Polaris, looks at the genetic makeup of prostate cancer cells and measures the presence or absence of markers that govern the aggressiveness of tumor growth.

"This is the eighth clinical study involving our Polaris test," said Peter Meldrum, Myriad’s president and CEO. "It is important for us to validate the effectiveness of our test multiple times in various populations of patients."

Meldrum said Myriad has worked with Intermountain Healthcare before, noting that five to six years ago the two joined to identify genes associated with various diseases. He anticipates the association will continue because Myriad has 13 new tests under development, including one that will use biochemical markers to determine if a patient is bipolar or suffering from major depression.

"We are thrilled to be partnering with Myriad to further research across a number of diseases in an effort to improve patient care," Dr. Brent Wallace, Intermountain’s chief medical officer, said in a statement.

He said the Polaris study, which will involve the analysis of biopsy samples from 200 patients diagnosed with prostate cancer, should help define the clinical benefits of the test.

"This will assist in helping men diagnosed with prostate cancer to understand the aggressiveness of their disease and make better informed decisions about appropriate treatment," Wallace said.

Although the financial details of the collaboration were not disclosed, Meldrum said Myriad will pay for the analysis of the biopsies, which will take place in Myriad’s laboratories. Intermountain will provide patient information.


story continues below
story continues below

steve@sltrib.com

Twitter: @OberbeckBiz



Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment


About Reader Comments


Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Videos
Jobs
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Login to the Electronic Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.